168 related articles for article (PubMed ID: 16858362)
1. [Pronounced lowering of low density cholesterol combined with elevation of high density cholesterol was associated with reduction of coronary atheroma. Results of ASTEROID trial].
Gratsianskiĭ NA
Kardiologiia; 2006; 46(5):71-3. PubMed ID: 16858362
[No Abstract] [Full Text] [Related]
2. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
Nissen SE; Nicholls SJ; Sipahi I; Libby P; Raichlen JS; Ballantyne CM; Davignon J; Erbel R; Fruchart JC; Tardif JC; Schoenhagen P; Crowe T; Cain V; Wolski K; Goormastic M; Tuzcu EM;
JAMA; 2006 Apr; 295(13):1556-65. PubMed ID: 16533939
[TBL] [Abstract][Full Text] [Related]
3. [Clinical study of the month: ASTEROID: regression of coronary atherosclerosis with rosuvastatin at a maximal daily dose of 40 mg].
Scheen AJ
Rev Med Liege; 2006 Apr; 61(4):267-72. PubMed ID: 16789616
[TBL] [Abstract][Full Text] [Related]
4. Med could reverse arterial blockages.
Health News; 2006 Jul; 12(7):13. PubMed ID: 16858860
[No Abstract] [Full Text] [Related]
5. Impact of intensive lipid lowering on lipid profiles over time and tolerability in stable coronary artery disease: insights from a subanalysis of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS).
Kawashiri MA; Yamagishi M; Sakamoto T; Takayama T; Hiro T; Daida H; Hirayama A; Saito S; Yamaguchi T; Matsuzaki M;
Cardiovasc Ther; 2013 Dec; 31(6):335-43. PubMed ID: 23409830
[TBL] [Abstract][Full Text] [Related]
6. Factors underlying regression of coronary atheroma with potent statin therapy.
Puri R; Nissen SE; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; St John J; Wolski K; Uno K; Kataoka Y; Nicholls SJ
Eur Heart J; 2013 Jun; 34(24):1818-25. PubMed ID: 23644179
[TBL] [Abstract][Full Text] [Related]
7. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN.
Puri R; Libby P; Nissen SE; Wolski K; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K; Kataoka Y; Tuzcu EM; Nicholls SJ
Eur Heart J Cardiovasc Imaging; 2014 Apr; 15(4):380-8. PubMed ID: 24448227
[TBL] [Abstract][Full Text] [Related]
8. High-dose statins and atherosclerosis regression.
Port SC
JAMA; 2006 Oct; 296(15):1836; author reply 1837. PubMed ID: 17047208
[No Abstract] [Full Text] [Related]
9. Effect of two intensive statin regimens on progression of coronary disease.
Nicholls SJ; Ballantyne CM; Barter PJ; Chapman MJ; Erbel RM; Libby P; Raichlen JS; Uno K; Borgman M; Wolski K; Nissen SE
N Engl J Med; 2011 Dec; 365(22):2078-87. PubMed ID: 22085316
[TBL] [Abstract][Full Text] [Related]
10. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS).
Takayama T; Hiro T; Yamagishi M; Daida H; Hirayama A; Saito S; Yamaguchi T; Matsuzaki M;
Circ J; 2009 Nov; 73(11):2110-7. PubMed ID: 19801853
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk.
Nicholls SJ; Uno K; Kataoka Y
Expert Rev Cardiovasc Ther; 2011 Nov; 9(11):1383-90. PubMed ID: 22059787
[TBL] [Abstract][Full Text] [Related]
12. HDL cholesterol and residual risk of first cardiovascular events.
Saely CH; Vonbank A; Drexel H
Lancet; 2010 Nov; 376(9754):1738; author reply 1738-9. PubMed ID: 21093648
[No Abstract] [Full Text] [Related]
13. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
[TBL] [Abstract][Full Text] [Related]
14. [Lipid lowering by rosuvastatin: how do statins differ?].
Laufs U
Dtsch Med Wochenschr; 2015 Mar; 140(5):313. PubMed ID: 25734669
[No Abstract] [Full Text] [Related]
15. Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID Study).
Wiviott SD; Mohanavelu S; Raichlen JS; Cain VA; Nissen SE; Libby P
Am J Cardiol; 2009 Jul; 104(1):29-35. PubMed ID: 19576317
[TBL] [Abstract][Full Text] [Related]
16. Exaggerated benefits of rosuvastatin compared with other statins.
Qizilbash N
Pharmacoepidemiol Drug Saf; 2009 May; 18(5):425-6. PubMed ID: 19382149
[No Abstract] [Full Text] [Related]
17. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
Jukema JW; Liem AH; Dunselman PH; van der Sloot JA; Lok DJ; Zwinderman AH
Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
[TBL] [Abstract][Full Text] [Related]
18. JUPITER strikes earth.
Fuster V; Bansilal S
Nat Clin Pract Cardiovasc Med; 2009 Mar; 6(3):159. PubMed ID: 19234496
[No Abstract] [Full Text] [Related]
19. Rosuvastatin and diabetes: when the evidences talk.
Barrios V; Escobar C
Cardiovasc Hematol Agents Med Chem; 2013 Jun; 11(2):115-24. PubMed ID: 23094943
[TBL] [Abstract][Full Text] [Related]
20. Review of efficacy of rosuvastatin 5 mg.
Teramoto T; Watkins C
Int J Clin Pract; 2005 Jan; 59(1):92-101. PubMed ID: 15707472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
